Best Peptides for Weight Loss
Research peptides offer several mechanisms for supporting fat loss — from FDA-approved GLP-1 receptor agonists with robust clinical trial data to growth hormone secretagogues shown to reduce visceral fat in controlled studies. This guide ranks the most studied options by evidence strength, mechanism, and practical utility.
Semaglutide and Tirzepatide are the FDA-approved gold standards. Retatrutide now has Phase 3 data (TRIUMPH-4, Dec 2025) showing 28.7% weight loss — the highest ever recorded in a clinical trial — but is not yet FDA-approved. For GH-based fat reduction, CJC-1295 + Ipamorelin is the most studied combination.
Evidence-Ranked Comparison
| Peptide | Evidence | |
|---|---|---|
#1Semaglutide | Strong Evidence | Full Profile → |
#2Tirzepatide | Strong Evidence | Full Profile → |
#3Retatrutide | Strong Evidence | Full Profile → |
#4CJC-1295 + Ipamorelin | Preliminary Evidence | Full Profile → |
#5AOD-9604 | Preliminary Evidence | Full Profile → |
Detailed Peptide Profiles
Semaglutide
Strong EvidenceFDA ApprovedGLP-1 RARCT Data15% average body weight reduction in STEP trials
Multiple Phase 3 RCTs (STEP 1–5). ~15% body weight reduction at 68 weeks. FDA-approved for obesity (Wegovy).
- FDA-approved (Wegovy)
- Robust Phase 3 data
- Cardiovascular benefit (SELECT trial)
- Once-weekly dosing
- GI side effects (nausea, vomiting)
- Cost
- Muscle mass loss without resistance training
Tirzepatide
Strong EvidenceFDA ApprovedDual AgonistBest EvidenceUp to 22.5% body weight reduction — best in class
SURMOUNT Phase 3 trials show 20–22.5% body weight reduction — superior to semaglutide. FDA-approved (Zepbound).
- Superior weight loss vs semaglutide
- Dual GLP-1 + GIP mechanism
- FDA-approved
- Improved insulin sensitivity
- GI side effects
- Higher cost
- Limited long-term cardiovascular data vs semaglutide
Retatrutide
Strong EvidencePhase 3 DataTriple AgonistInvestigational28.7% weight loss in Phase 3 — the highest of any obesity drug in clinical trials
TRIUMPH-4 Phase 3 (completed Dec 2025): 28.7% body weight reduction at 68 weeks on 12 mg — highest ever in a Phase 3 obesity trial. 58.6% of participants lost ≥25% bodyweight. TRIUMPH-1 & TRIUMPH-2 (obesity-only) results pending 2026; not yet FDA-approved.
- Highest Phase 3 weight loss ever recorded (28.7%)
- Triple agonist (GLP-1 + GIP + Glucagon)
- Once-weekly dosing
- Significant cardiovascular risk marker reduction
- ~80% liver fat reduction (MASH benefit)
- Not FDA-approved (filing expected 2026–2027)
- TRIUMPH-1/2 obesity-only results still pending
- Higher discontinuation rate (12–18% vs 4% placebo)
- Dysesthesia in up to 20.9% at 12 mg dose
CJC-1295 + Ipamorelin
Preliminary EvidenceResearch ChemicalGH SecretagogueStackElevates GH/IGF-1 → visceral fat reduction and lean mass preservation
Preclinical and small human studies show GH elevation and reduced visceral fat. No large RCTs for obesity.
- Preserves lean mass
- Improves body composition
- Better sleep quality
- Well-tolerated
- Not FDA-approved
- Limited human RCT data for fat loss
- Multiple injections needed
AOD-9604
Preliminary EvidenceResearch ChemicalHGH FragmentSpecificTargets fat metabolism directly without glucose or IGF-1 effects
HGH fragment targeting fat metabolism. Phase 2b data shows modest effects. No blood glucose impact.
- Specific fat-burning mechanism
- No glucose impact
- No IGF-1 elevation
- Good safety profile
- Limited efficacy data
- Phase 2b showed modest results
- Short half-life
Research Background
How GLP-1 Peptides Promote Fat Loss
GLP-1 receptor agonists (Semaglutide, Tirzepatide, Retatrutide) work through multiple complementary mechanisms: they slow gastric emptying — extending the feeling of satiety after meals — and act centrally on hypothalamic neurons that regulate appetite and food intake. Tirzepatide adds GIP receptor agonism for enhanced insulin response and lipolysis. Retatrutide goes further by adding glucagon receptor agonism, which directly increases basal metabolic rate (thermogenesis) and drives hepatic lipolysis — resulting in the highest weight loss ever recorded in a Phase 3 trial: 28.7% at 68 weeks (TRIUMPH-4, December 2025). This glucagon component also produces ~80% liver fat reduction, making retatrutide a potential first-in-class treatment for MASH.
Why Retatrutide Is Called "Godzilla" — and Why It's Justified
The r/Retatrutide community started calling it "Godzilla" after Phase 2 results landed — and Phase 3 made the nickname stick. Three things set it apart from every prior weight-loss drug: (1) The weight loss doesn't plateau. Semaglutide and tirzepatide users typically stall at 40–48 weeks; retatrutide participants in TRIUMPH-4 were still losing weight at week 68. (2) The numbers are surgical. 39.4% of TRIUMPH-4 participants lost 30% or more of their body weight — outcomes previously only seen with bariatric surgery. (3) It breaks plateaus. Researchers report that study subjects who stalled on semaglutide or tirzepatide saw weight loss resume on retatrutide, consistent with its thermogenic glucagon mechanism addressing the metabolic adaptation that causes GLP-1 stalls. The community is also describing a total elimination of 'food noise' — an absence of background food craving stronger than what users report from tirzepatide. This matches the triple-receptor mechanism: glucagon receptor agonism appears to quiet reward-driven eating pathways beyond what GLP-1/GIP achieves alone.
Growth Hormone Secretagogues vs GLP-1 Agonists
While GLP-1 agonists directly reduce caloric intake and have robust clinical data for weight loss, growth hormone secretagogues (CJC-1295, Ipamorelin, Sermorelin) work differently — they stimulate pulsatile GH release, which in turn drives IGF-1 production, reduces visceral adipose tissue, and supports lean muscle mass. The clinical evidence is far less developed than for GLP-1 agonists, but these peptides may be valuable for research protocols targeting body composition improvement and metabolic health holistically.
Legal and Regulatory Status
Semaglutide (Wegovy for obesity, Ozempic for T2D) and Tirzepatide (Zepbound for obesity, Mounjaro for T2D) are FDA-approved medications. Retatrutide has completed its first Phase 3 trial (TRIUMPH-4, December 2025) and Eli Lilly is expected to file an NDA with the FDA in 2026–2027 pending TRIUMPH-1 and TRIUMPH-2 results; it remains investigational. AOD-9604, CJC-1295, and Ipamorelin are research chemicals not approved for human use in most jurisdictions. Regulatory status varies by country — always verify local laws.
Research & Educational Use Only: All peptides and compounds referenced in this guide are research chemicals documented for scientific education. This content does not constitute medical advice. All compounds should only be used for legitimate laboratory research in accordance with applicable laws. Consult a licensed physician or researcher before any use.
Frequently Asked Questions
Which peptide causes the most weight loss?
As of 2026, Retatrutide holds the highest Phase 3 weight loss result ever recorded: 28.7% at 68 weeks (TRIUMPH-4, December 2025). This surpasses Tirzepatide (~22.5% in SURMOUNT-1) and Semaglutide (~14.9% in STEP 1). However, Semaglutide and Tirzepatide are the only FDA-approved options — Retatrutide's pivotal obesity-only trials (TRIUMPH-1 & TRIUMPH-2) are still ongoing with results expected in 2026.
Are weight-loss peptides safe?
FDA-approved GLP-1 agonists (Semaglutide, Tirzepatide) have extensive safety data from clinical trials. Common side effects include nausea, vomiting, and GI discomfort. Research chemicals like CJC-1295, Ipamorelin, and AOD-9604 have limited human safety data and are not approved for human use.
What is the best peptide for fat loss without losing muscle?
For body composition (reducing fat while preserving muscle), GH secretagogues like CJC-1295 + Ipamorelin are studied for their dual effect on GH/IGF-1 elevation. GLP-1 agonists may cause some lean mass loss if used without resistance training.
How long do peptides take to work for weight loss?
FDA-approved GLP-1 agonists are typically titrated over 16–20 weeks and show measurable weight loss within 8–12 weeks. Research peptides like CJC-1295 + Ipamorelin are typically cycled in 12-week research protocols.
Related Research Guides
Want to compare peptides interactively?
Use our interactive comparison tool or stack builder to design your research protocol.